Dr. Hideaki Miyake

Dr. Hideaki Miyake

M.D. Kobe University (Kobe, Japan), 1993 
Ph.D. Kobe University (Kobe, Japan), 1998 
Postdoctoral fellowship, Vancouver Prostate Centre (Vancouver, Canada), 1998-2000

Team: 
Associate Members
Positions: 

Associate Professor, Division of Urology, Kobe University Graduate School of Medicine (Kobe, Japan)
Active Staff, Kobe University Hospital (Kobe, Japan)

 

After graduating from Kobe University Graduate school of Medicine, Dr. Miyake joined the Vancouver Prostate Centre as a postdoctoral fellow in 1998. He worked with Dr. Martin Gleave investigating the molecular mechanisms involved in the progression of prostate cancer to androgen-independence and the development of a novel therapeutic strategy targeted against antiapoptotic genes using antisense oligonucleotide technology. To date, he has published more than 300 peer-reviewed papers, including 46 under joint authorship with Dr. Gleave. He is a recipient of many awards, such as the First prize in the Essay Contest at the CUA annual meeting in 1999, First prize in the Essay Contest at the AUA annual meeting in 2000 and Best Paper Award of the Clinical Section at the JUA annual meeting in 2008.

Dr. Miyake’s current research focuses on a wide range of topics associated with urological oncology, including the role of inflammatory cytokines as activators of androgen receptor, the impact of the prostate's microenvironment on local aggressiveness of prostate cancer and the overcoming of acquired resistance of renal cancer to molecular targeted agents. Moreover, he has tried to develop novel therapies for urological cancers by combining conventional therapeutic modalities and OGX-011, an antisense oligonucleotide inactivating the cytoprotective chaperon clusterin, in collaboration with Dr. Gleave.

Dr. Miyake is currently playing a central role in the Division of Urology, Kobe University Hospital as a clinical scientist and urologic surgeon. Therefore, he is also performing a number of clinical studies focusing on a wide variety of interesting topics, such as the development of extended radical prostatectomy for locally advanced prostate cancer, the improvement of functional outcomes in bladder cancer patients with orthotopic neobladder and the assessment of useful sequential therapy for metastatic renal cancer using molecular targeted agents. In addition, as the Chair of the Urological Oncology Group at Kobe University Hospital, he provides access for patients with urological cancer to the latest clinical trials using novel drugs.

A World Class Centre

The Vancouver Prostate Centre (VPC) has a track record of success that has earned it a reputation as one of the world’s most respected cancer facilities. It is a National Centre of Excellence and a designated Centre of Excellence for Commercialization and Research.

Events

VPC Terry Fox team 2016

Terry Fox Run: Sunday September 16, 2018

On Sunday September 16, the fundraising Terry Fox walk/run/ride is taking place across Canada.  We are grateful for our  grant support provided by The Terry Fox Foundation and Terry Fox Research Institute continously since 1998 - click here to donate to our team (opens in new window)

 

Vancouver

18th Annual Pacific Northwest Prostate Cancer Conference: Sat Sept 22, 2018

The 18th Annual Pacific Northwest Prostate Cancer Conference for patients, their families and health care professionals will be held in Vancouver on Saturday September 22, from 8 AM to 4 PM.  Click here for further details and to purchase tickets ($30, includes lunch). (Opens in new window)

 

Employment

Work at the Vancouver Prostate Centre

Thursday, July 26, 2018

Dr. Gleave awarded the 2018 Dr. Chew Wei Memorial Prize in Cancer Research

Dr. Gleave
Tuesday, May 29, 2018

Three VPC trainees receive 2018 VCHRI Rising Star Awards

2018 Rising Star Awardees
DNA

Make A Difference

Help the Vancouver Prostate Centre fund research to find better treatments and a cure.